Using modified RNA to improve COVID-19 vaccines
microRNA-controlled mRNA therapeutics
This study is looking at new types of RNA vaccines to boost your immune response against COVID-19 by figuring out the best ways to deliver them to the right cells in your body, which could make the vaccines work even better for you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11057570 on NIH RePORTER |
What this research studies
This research focuses on developing nucleoside modified RNA-based drugs, particularly RNA vaccines, to enhance the immune response against COVID-19. The approach involves delivering modRNA through lipid nanoparticles to specific cell types, which can influence how T cells are activated. By understanding which cells present the antigens and how they affect immune responses, the research aims to improve the effectiveness of these vaccines. The study also explores ways to target the delivery of modRNA to specific cells, potentially leading to better therapeutic outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals who are at risk for COVID-19 or those who may benefit from enhanced vaccination strategies.
Not a fit: Patients who are not at risk for COVID-19 or those who have already received effective vaccination may not receive additional benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective COVID-19 vaccines that provide stronger and more targeted immune responses.
How similar studies have performed: Other research has shown success with similar approaches in RNA vaccine development, particularly in the context of COVID-19.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Brown, Brian D — Icahn School of Medicine at Mount Sinai
- Study coordinator: Brown, Brian D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.